Entero Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENTO research report →
Price Chart
About the company
Entero Therapeutics, Inc. , a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.
- CEO
- Jason David Sawyer
- IPO
- 2016
- Employees
- 2
- HQ
- Boca Raton, FL, US
Get TickerSpark's AI analysis on ENTO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.58M
- P/E
- -0.80
- Fwd P/E
- 2.11
- PEG
- -0.06
- P/S
- 169.32
- P/B
- 0.74
- EV/EBITDA
- -1.78
- Div Yield
- 0.00%
- Gross Margin
- -775.58%
- Op Margin
- -13264.41%
- Net Margin
- -11664.78%
- ROE
- -18.69%
- ROIC
- -26.65%
Latest fiscal year · YoY change
- Revenue
- $36.25K+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-7,083,438
- Net Income
- $-6,553,578+63.7%
- EPS
- $-4.16-7.2%
- OCF Growth
- +38.1%
- FCF Growth
- +38.1%
- 52W High
- $5.84
- 52W Low
- $0.97
- 50D MA
- $4.07
- 200D MA
- $2.24
- Beta
- 1.19
- RSI (14)
- 40
- Avg Volume
- 216.27K
No earnings-call transcripts are available for ENTO yet.
- Free Float
- 93.2%
- Shares Outstanding
- 4.77M
- Float Shares
- 4.44M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 24 | SAPIRSTEIN JAMES | sell | 1,289 |
| Jun 11, 24 | KHOSLA CHAITAN PHD | other | 24,889 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENTO coverage
Recent articles, reports, and earnings notes.
No research on ENTO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENTO report →Entero Therapeutics (NASDAQ:ENTO) Shares Down 3.4% – Should You Sell?
defenseworld.net · Apr 25
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
accessnewswire.com · Nov 28
ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer
accessnewswire.com · Nov 19
Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy
accessnewswire.com · Nov 13
Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid
accessnewswire.com · Nov 6
Entero's Reinvention Gives the Grid, AI, and Investors Exactly What They're After: Power and Value (NASDAQ: ENTO)
accessnewswire.com · Oct 30
Entero Regains Nasdaq Compliance With Grid AI Acquisition
accessnewswire.com · Oct 30
Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid
accessnewswire.com · Oct 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.